NBS NEWZZZ $12M CASH FROM ERYE CLOSURE // NeoStem Closes

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2012 at 10:26 AM

[b]NBS > NEWZZZ $12M CASH FROM ERYE CLOSURE [/b]// NeoStem Closes Divestiture of Its Ownership Interest in Suzhou Erye

2012-11-13 09:08 ET - News Release

NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE:NBS) ("NeoStem" or the "Company"), an emerging market leader in the fast growing cell therapy industry, today announced that the Company has completed the divestiture of its 51% ownership interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), a China-based generic pharmaceutical company. The divestiture provides NeoStem with $12,280,000 in cash and removes from the Company's balance sheet over $30 million in short and long-term debt obligations. Erye also returns 1,040,000 shares representing approximately 0.7% of the Company's outstanding common stock, 1,170,000 stock options representing approximately 5.1% of the Company's outstanding options and 640,000 warrants to purchase common stock held by Erye representing approximately 1.1% of the Company's outstanding warrants.

"We are very pleased to have reached this significant milestone in our business," said Dr. Robin Smith, Chairman and CEO of NeoStem. "The Erye divestiture brings non-dilutive capital that bolsters our cash position in the United States, reduces legal and financial reporting expenditures, simplifies our financial statements and focuses our efforts exclusively on the rapidly growing cell therapy industry. The divestiture also paves the way for the Company to qualify for new funding through the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program which would support our pre-clinical development of VSELTM Technology. NeoStem will also be able to invest more resources into its cell therapy development and contract manufacturing activities."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic product candidate, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSEL TM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: For more information, please contact:
Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sinopec Unveils Biodiversity Report at COP17

Sinopec's First Step on the Global Biodiversity Stage Seems like Sinopec (HKG: 0386) has decided to toss its hat into the biodiversity conservation ring. At COP17 in Armenia, they released their inaugural Global Biodiversity Conservation Report—an event that marks more than just a company selling oil and gas. Now, they're talking wildlife and ecologies. Is that irony,...

NumbersGame's Bold Integration Ups the Accounting Ante

Integrating the Heavy Hitters: Stripe, Square, and Ramp Diving headfirst into the mix, NumbersGame's recent move to open up integration with heavyweights like Stripe, Square, and Ramp is nothing short of a game-changer for accountants in the field. If you’re an accounting firm handling multiple clients, brace yourself—these latest enhancements might just redefine the...

Fresha Teams with Klarna: Shaking Up Beauty Payments

New Flexibility at the Beauty Checkout Hey, if you've ever paced back and forth considering signing up for that luxury self-care spree, well, Fresha’s latest move might just tip the scales. The beauty and wellness booking giant has partnered with Klarna, diving headfirst into the Buy Now, Pay Later (BNPL) craze. It's about time, right? Everyone loves a good spa session,...

Oracle's $20 Billion Offering: What Investors Need to Know

Oracle's Big Play: A $20 Billion Offering Nobody said playing in the big leagues was easy, and Oracle seems to be doubling down on that idea. Today, they spilled the beans on their ambition to rake in a cool $20 billion through an offering of common stock and senior notes. For those of us who keep a close eye on NYSE:ORCL, this is more than just a number—it's a signal...

TriMas Streamlines Portfolio with Rapak Sale

TriMas Sheds Rapak: A Strategic Move Here's a twist worth dissecting: TriMas Corporation (NASDAQ: TRS) has offloaded its subsidiary Rapak, LLC to the German industrial packaging giant, Ringmetall SE. This isn't just a business shuffle—it's a calculated pivot with eyes on sharpening the core business blade. As they announced from Bloomfield Hills, Michigan, this move...

Platinum Equity's Bold Move on Warren Valve: An Analysis

A Big Play in the Valve Game Straight out of the industrial playbook, Platinum Equity swoops in with its latest acquisition of Warren Valve, yanking it from the clutches of Allied Group. It's not every day you see a move like this in the flow control world. Yeah, you heard that right—flow control. The kind of business that’s all about ensuring the right stuff gets to...

Extreme Weather Survivors Rally for Change with 'Stolen Summers'

Lighting a Fire Under Complacency Elections often bring out the big dogs, but rarely do you see a grassroots campaign like Extreme Weather Survivors’ 'Stolen Summers' making such ripples. Rallying from New York to North Carolina and everywhere in between, this campaign has been a clarion call for communities ravaged by Mother Nature's fury. And let's face it, the...

Clarivate Integrates Trademark Data with Microsoft AI

You know, the market's all abuzz with AI this, AI that. But today, we're getting a glimpse at something that isn't just hyped-up vaporware; it's actually useful. Clarivate Plc (NYSE:CLVT), which has carved a niche in transformative intelligence, is teaming up with Microsoft to slide their CompuMark trademark data into Microsoft Copilot via something they call IPOne. It's...

Ascletis Showcases Bold Moves in Obesity Drug Arena

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

Immunic's November Moves: Conferences and Clinical Trials

Immunic Taps Into November Conferences Every now and then, you catch a company that's not just spinning its wheels but making some potentially big waves in their field. This time, it's Immunic, Inc. (Nasdaq: IMUX), stepping into the spotlight. They're strutting their stuff at several investor conferences this November, starting with Boston and New York, then hopping over...